Lung-selective 25-hydroxycholesterol nanotherapeutics as a suppressor of COVID-19-associated cytokine storm
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyelim | - |
dc.contributor.author | Lee, Han Sol | - |
dc.contributor.author | Ahn, June Hong | - |
dc.contributor.author | Hong, Kyung Soo | - |
dc.contributor.author | Jang, Jong Geol | - |
dc.contributor.author | An, Jiseon | - |
dc.contributor.author | Mun, Yong-Hyeon | - |
dc.contributor.author | Yoo, So-Yeol | - |
dc.contributor.author | Choi, Yoon Jung | - |
dc.contributor.author | Yun, Mi-Young | - |
dc.contributor.author | Song, Gyu Yong | - |
dc.contributor.author | Joo, Jinmyoung | - |
dc.contributor.author | Na, Dong Hee | - |
dc.contributor.author | Kim, Hong Nam | - |
dc.contributor.author | Park, Hee Ho | - |
dc.contributor.author | Lee, Jae-Young | - |
dc.contributor.author | Lee, Wonhwa | - |
dc.date.accessioned | 2023-09-11T01:37:26Z | - |
dc.date.available | 2023-09-11T01:37:26Z | - |
dc.date.created | 2023-07-21 | - |
dc.date.issued | 2021-06 | - |
dc.identifier.issn | 1748-0132 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/190289 | - |
dc.description.abstract | In response to the coronavirus disease-19 (COVID-19) pandemic caused by severe acute respiratory syn-drome coronavirus 2 (SARS-CoV-2), global efforts are focused on the development of new therapeutic in-terventions. For the treatment of COVID-19, selective lung-localizing strategies hold tremendous potential, as SARS-CoV-2 invades the lung via ACE2 receptors and causes severe pneumonia. Similarly, recent reports have shown the association of COVID-19 with decreased 25-hydroxycholesterol (25-HC) and increased cytokine levels. This mechanism, which involves the activation of inflammatory NF-kappa B-and SREBP2-mediated inflammasome signaling pathways, is believed to play a crucial role in COVID-19 pathogenesis, inducing acute respiratory distress syndrome (ARDS) and sepsis. To resolve those clinical conditions ob-served in severe SARS-CoV-2 patients, we report 25-HC and didodecyldimethylammonium bromide (DDAB) nanovesicles (25-HC@DDAB) as a COVID-19 drug candidate for the restoration of intracellular cholesterol level and suppression of cytokine storm. Our data demonstrate that 25-HC@DDAB can selectively accu-mulate the lung tissues and effectively downregulate NF-kappa B and SREBP2 signaling pathways in COVID-19 patient-derived PBMCs, reducing inflammatory cytokine levels. Altogether, our findings suggest that 25-HC@DDAB is a promising candidate for the treatment of symptoms associated with severe COVID-19 pa-tients, such as decreased cholesterol level and cytokine storm. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.title | Lung-selective 25-hydroxycholesterol nanotherapeutics as a suppressor of COVID-19-associated cytokine storm | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Hee Ho | - |
dc.identifier.doi | 10.1016/j.nantod.2021.101149 | - |
dc.identifier.scopusid | 2-s2.0-85104142126 | - |
dc.identifier.wosid | 000670246400002 | - |
dc.identifier.bibliographicCitation | NANO TODAY, v.38 | - |
dc.relation.isPartOf | NANO TODAY | - |
dc.citation.title | NANO TODAY | - |
dc.citation.volume | 38 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Nanoscience & Nanotechnology | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Multidisciplinary | - |
dc.subject.keywordPlus | DIDODECYLDIMETHYLAMMONIUM BROMIDE | - |
dc.subject.keywordPlus | Chylomicrons | - |
dc.subject.keywordPlus | Lipoproteins | - |
dc.subject.keywordPlus | Inflammation | - |
dc.subject.keywordPlus | Cholesterol metabolism | - |
dc.subject.keywordPlus | Endotoxin | - |
dc.subject.keywordPlus | Severity | - |
dc.subject.keywordPlus | Sepsis | - |
dc.subject.keywordPlus | Serum | - |
dc.subject.keywordAuthor | Severe COVID-19 | - |
dc.subject.keywordAuthor | Lung-selective nanohybrids | - |
dc.subject.keywordAuthor | Sepsis | - |
dc.subject.keywordAuthor | 25-hydroxycholesterol | - |
dc.subject.keywordAuthor | Didodecyldimethylammonium bromide | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1748013221000748?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.